This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.
Trial Name: A Phase III Trial of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer.
Protocol ID: RTOG 1005
Pathologically proven diagnosis of breast cancer resected by lumpectomy and whole breast irradiation with boost without regional nodal irradiation planned.
Patient must be female
Age > 18
Must meet required laboratory values
Women of childbearing potential must not be pregnant, non-lacting and willing to use medically acceptable form of contraception during radiation therapy.
Prior invasive non-breast malignancy (except non-melanomatous skin cancer, carcinoma in situ if the cervix) unless disease free for a minimum of 5 years prior to registration.
Prior invasive or in-situ carcinoma of the breast (-prior LCIS is eligible)
Paget’s disease of the nipple
Male breast cancer
Pregnancy or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception.
Active systemic lupus, erythematosus, or any history of scleroderma, dermatomyositis with active rash.
Enrollment: •About 2312 people will take part in this study at several medical centers
Taking part in this study may or may not make your health better.While researchers hope that this method of administering radiation therapy over 3 weeks will be as useful against cancer compared to the usual treatment given over a longer period of time, there is no proof of this yet.We do know that the information from this study will help researchers learn more about using larger daily doses of radiation therapy for fewer treatments in a shorter period of time as a treatment for cancer.This information could help future cancer patients.
These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353.